Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

QUOTED. 30 August 2019. Jackie Kunzler.

Executive Summary

A Medical Device Innovation Consortium (MDIC) workgroup has partnered with Pathway for Patient Health to create a Quality Science Education framework that can be used by any university free-of-charge. See what Jackie Kunzler, a chief quality officer for device-maker Baxter International, said about it here.

"When I came to the quality department at Baxter four years ago, I was assessing the talent, and what I found was that I had a bunch of history and English majors who fell into quality because they had nowhere else to go. [That's] why we need to establish a quality discipline at the university level to educate students about the benefits of making quality part of their future career." – Jackie Kunzler, chief quality officer, Baxter International Inc.

Click here for a free trial of Medtech Insight

 

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT125560

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel